Cytometric Therapies for Cell Delivery
Maximizing Efficacy of Cell Delivery
Oak Ridge National Laboratory
Contact ORNL About This Technology
Technology Marketing SummaryStem cell therapies are a viable treatment options for some human diseases. Efficacy of such therapies can be maximized by addressing critical issues such as cell delivery and cell survival post delivery. Conventional methods for cell delivery do not determine the viability of the transplanted cell. For example, an estimated 5?10% of cells transplanted into the central nervous system survive post?transplantation, leaving only a small portion of the originally grafted cells to contribute in functional restoration.
DescriptionScientists at ORNL and scientists at Virginia Commonwealth University and the University of Virginia have developed a system to overcome this problem through cytometric monitoring of stem cell delivery into host tissues via a neurocatheter.
Benefits
Means and Methods for Cytometric Therapies (UTB - ID 1820) patent pending
Lead UTB Inventor
Dr. Stephen W. Allison
Dr. Boyd M. EvansTechnology Status
DescriptionScientists at ORNL and scientists at Virginia Commonwealth University and the University of Virginia have developed a system to overcome this problem through cytometric monitoring of stem cell delivery into host tissues via a neurocatheter.
Benefits
- Quantization of the distribution of stem cells for human therapies
- Confirm cell count during stem cell delivery
- Minimize delivery time and tissue damage while maximizing chances for implant survival
- Provide a variety of useful physiological data for optimization of the therapeutic approach
- This system can be used with conventional cell delivery methods
Means and Methods for Cytometric Therapies (UTB - ID 1820) patent pending
Lead UTB Inventor
Dr. Stephen W. Allison
Dr. Boyd M. EvansTechnology Status
Technology ID | Development Stage | Availability | Published | Last Updated |
---|---|---|---|---|
1820 | Development | Available | 09/22/2012 | 09/22/2012 |